The effectiveness of intravenous Midazolam for children undergoing echocardiography at Vietnam National Children’s hospital

Abstract

Objective: Initial evaluation of the effectiveness and side effects of intravenous midazolam for children undergoing echocardiography at the Department of Outclinic Cardiac Exam and Diagnosis, Heart Center, Vietnam National Children’s Hospital. Subjects and methods: From Decber 2022 to March 2023, a prospective, cross-sectional study using a convenience sample was conducted to examine the effectiveness of of intravenous midazolam on 312 children undergoing echocardiography at Department of Outclinic Cardiac Exam and Diagnosis , Vietnam National Children’s Hospital. Results: The median age and median weight of children in the study were 12 months (IQR = 15.4) and 8 kg(IQR = 3.6), respectively. Only 13 children (4.2%) needed the second dose of Midazolam to complete the echocardiography with a lower dose of of 0.125mg/kg/time (IQR = 0.06) compared to the first one. The median duration of the medication in effect was 5 minutes (IQR = 3.2). There were no children experiencing with signs of anaphylaxis, cyanosis, convulsions, respiratory failure or apnea. Conclusion: It is likely that the use of intravenous Midazolam for children is effective in promoting their collaboration with healthcare staff while minimising side effects during echocardiography procedures